Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...

Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November ...

On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...

Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Fintel reports that on October 30, 2024, B of A Securities upgraded their outlook for Incyte (NasdaqGS:INCY) from Neutral to ...

Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.

Total revenues of $1,138 million in the third quarter (Q3'24) (+24% Y/Y) Jakafi ® (ruxolitinib) net product revenues of $741 ...

Incyte ( (INCY) ) has realeased its Q3 earnings. Here is a breakdown of the information Incyte presented to its investors. Incyte Corporation ...